Skip to main content

Table 3 Comparison of ECV using actual and synthetic Hct between myocardial disease or coronary artery disease and control group

From: Native T1 mapping and extracellular volume fraction for differentiation of myocardial diseases from normal CMR controls in routine clinical practice

Group Mid LV short-axis ECV
with actual Hct
(%)
Septum ECV
with actual Hct
(%)
Mid LV short-axis ECV
with synthetic Hct
(%)
Septum ECV
with synthetic Hct
(%)
n Mean ± SD 95% CI p n Mean ± SD 95% CI p n Mean ± SD 95% CI P n Mean ± SD 95% CI p
Amyloidosis (n = 8) 42.8 ± 9.0 35.3–50.3 0.002 (n = 8) 47.2 ± 10.5 38.4–56.0 0.001 (n = 11) 46.6 ± 13.0 38.9–54.3 0.001 (n = 11) 49.3 ± 11.8 41.4–57.2 < 0.001
DCM
(n = 116)
28.9 ± 4.1 28.1–29.6 < 0.001 (n = 116) 29.9 ± 4.5 29.1–30.8 < 0.001 (n = 157) 28.9 ± 3.6 28.4–29.5 < 0.001 (n = 157) 30.0 ± 3.9 29.4–30.6 < 0.001
HCM
(n = 84)
28.7 ± 4.6 27.7–29.7 0.002 (n = 84) 30.1 ± 4.6 29.1–31.1 < 0.001 (n = 112) 29.7 ± 5.7 28.6–30.7 < 0.001 (n = 112) 31.1 ± 5.8 30.0-32.2 < 0.001
Myocarditis (n = 13) 30.6 ± 7.8 25.9–35.4 0.126 (n = 13) 30.5 ± 5.7 27.1–34.0 0.125 (n = 17) 31.4 ± 7.7 27.7–35.1 0.030 (n = 17) 31.3 ± 5.3 28.6–34.1 0.014
CAD
(n = 223)
28.1 ± 5.0 27.5–28.7 0.006 (n = 186) 29.3 ± 5.5 28.5–30.1 0.002 (n = 293) 27.8 ± 4.3 27.3–28.3 0.002 (n = 247) 29.1 ± 4.9 28.5–29.7 < 0.001
Control
(n = 465)
27.1 ± 3.4 26.8–27.4 (n = 465) 27.9 ± 3.6 27.6–28.3 (n = 595) 26.9 ± 3.1 26.7–27.2 (n = 595) 27.0 ± 3.3 27.5–28.0
  1. A p-value < 0.05 indicates statistical significance
  2. ECV extracellular volume fraction, Hct hematocrit, CAD coronary artery disease, SD standard deviation, CI confidence interval, DCM dilated cardiomyopathy, HCM hypertrophic cardiomyopathy